Actively Recruiting
Study of BTKi-Rituximab Followed by Glofitamab Treatment in High-Risk Untreated Mantle Cell Lymphoma Patients
Led by M.D. Anderson Cancer Center · Updated on 2026-05-20
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating if giving glofitamab after initial treatment with BTKi-rituximab can help control high-risk mantle cell lymphoma MCL in patients who have not been treated before. This phase 2 study aims to determine how well patients achieve minimal residual disease MRD negativity and complete response after receiving these treatments. The study also seeks to assess overall response, progression-free survival, overall survival, and the safety of glofitamab as a consolidation therapy. Participants will first receive induction treatment with BTKi-Rituximab, which includes oral Acalabrutinib or Zanubrutinib and intravenous Rituximab. Those who achieve complete response will then receive consolidation treatment with intravenous glofitamab over 12 cycles. After consolidation, maintenance treatment with BTKi-Rituximab will continue. This treatment sequence is designed to evaluate the combined effects of these therapies on high-risk MCL. During the study, participants will undergo regular evaluations including disease assessments, laboratory tests, and safety monitoring for adverse events throughout approximately one year. Researchers will measure treatment response using criteria such as metabolic response by imaging and track the occurrence of side effects. The study involves a non-randomized design and includes follow-up to monitor long-term outcomes and treatment safety.
CONDITIONS
Brief Title
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
Research Team
P
Preetesh Jain, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here